Emerging patterns in HIV integrase resistance

Margarida Veloso; Marta Ribeiro; Joaquim Cabanas; Fátima Gonçalves; Sandra Fernandes; Isabel Diogo; Inês Costa; Victor Pimentel; Marta Pingarilho; Ana Abecasis; Perpétua Gomes

doi:10.1097/QAD.0000000000004322

Emerging patterns in HIV integrase resistance

Margarida Veloso
, Marta Ribeiro
, Joaquim Cabanas
, Fátima Gonçalves
, Sandra Fernandes
, Isabel Diogo
, Inês Costa
, Victor Pimentel
, Marta Pingarilho
, Ana Abecasis
, Perpétua Gomes

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We assessed integrase resistance in 837 treatment-experienced people with HIV (PWH) with virological failure (2022–2024) in Portugal. Major resistance mutations were found in 5.5%, with N155H and R263K being the most common. Resistance was more frequent in non-B subtypes and often co-occurred with resistance to other antiretroviral classes. Though prevalence remains low, the findings highlight the need for continued surveillance to inform treatment decisions, especially as integrase inhibitors like dolutegravir, bictegravir and cabotegravir become more widely used.

Original language	English
Pages (from-to)	2324-2327
Number of pages	4
Journal	AIDS
Volume	39
Issue number	15
DOIs	https://doi.org/10.1097/QAD.0000000000004322
Publication status	Published - 1 Dec 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/QAD.0000000000004322

Cite this

@article{408718b0e1534e9f9cadeb25f1f607a2,

title = "Emerging patterns in HIV integrase resistance",

abstract = "We assessed integrase resistance in 837 treatment-experienced people with HIV (PWH) with virological failure (2022–2024) in Portugal. Major resistance mutations were found in 5.5\%, with N155H and R263K being the most common. Resistance was more frequent in non-B subtypes and often co-occurred with resistance to other antiretroviral classes. Though prevalence remains low, the findings highlight the need for continued surveillance to inform treatment decisions, especially as integrase inhibitors like dolutegravir, bictegravir and cabotegravir become more widely used.",

author = "Margarida Veloso and Marta Ribeiro and Joaquim Cabanas and F{\'a}tima Gon{\c c}alves and Sandra Fernandes and Isabel Diogo and In{\^e}s Costa and Victor Pimentel and Marta Pingarilho and Ana Abecasis and Perp{\'e}tua Gomes",

note = "Copyright {\textcopyright} 2025 The Author(s). Published by Wolters Kluwer Health, Inc.",

year = "2025",

month = dec,

day = "1",

doi = "10.1097/QAD.0000000000004322",

language = "English",

volume = "39",

pages = "2324--2327",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "15",

}

TY - JOUR

T1 - Emerging patterns in HIV integrase resistance

AU - Veloso, Margarida

AU - Ribeiro, Marta

AU - Cabanas, Joaquim

AU - Gonçalves, Fátima

AU - Fernandes, Sandra

AU - Diogo, Isabel

AU - Costa, Inês

AU - Pimentel, Victor

AU - Pingarilho, Marta

AU - Abecasis, Ana

AU - Gomes, Perpétua

PY - 2025/12/1

Y1 - 2025/12/1

N2 - We assessed integrase resistance in 837 treatment-experienced people with HIV (PWH) with virological failure (2022–2024) in Portugal. Major resistance mutations were found in 5.5%, with N155H and R263K being the most common. Resistance was more frequent in non-B subtypes and often co-occurred with resistance to other antiretroviral classes. Though prevalence remains low, the findings highlight the need for continued surveillance to inform treatment decisions, especially as integrase inhibitors like dolutegravir, bictegravir and cabotegravir become more widely used.

AB - We assessed integrase resistance in 837 treatment-experienced people with HIV (PWH) with virological failure (2022–2024) in Portugal. Major resistance mutations were found in 5.5%, with N155H and R263K being the most common. Resistance was more frequent in non-B subtypes and often co-occurred with resistance to other antiretroviral classes. Though prevalence remains low, the findings highlight the need for continued surveillance to inform treatment decisions, especially as integrase inhibitors like dolutegravir, bictegravir and cabotegravir become more widely used.

UR - https://www.scopus.com/pages/publications/105021798473

U2 - 10.1097/QAD.0000000000004322

DO - 10.1097/QAD.0000000000004322

M3 - Article

C2 - 41235656

AN - SCOPUS:105021798473

SN - 0269-9370

VL - 39

SP - 2324

EP - 2327

JO - AIDS

JF - AIDS

IS - 15

ER -

Emerging patterns in HIV integrase resistance

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this